Protect the ability to think, learn, remember, decide and remain independent — before spending heavily on brain scans, biomarkers, nootropics or “brain-age” technology.

The objective is not simply to “prevent Alzheimer’s”. The National Institute on Aging defines brain health much more broadly, covering cognitive function, movement, emotional function and sensory abilities such as hearing and vision. The World Health Organization takes an equally functional view of healthy ageing: maintaining the capacities to learn and make decisions, move, build relationships, meet basic needs and contribute to society.

That broader definition is useful because many of the best investments in the ageing brain are surprisingly ordinary:

blood pressure → exercise → sleep → hearing and vision → metabolic health → learning → social engagement → mental health.

Only after those foundations does it make sense to ask whether cognitive testing, genetics, Alzheimer’s biomarkers, MRI-derived “brain age”, neurostimulation or expensive brain-health programmes add enough information to justify their cost.

The question is therefore not:

“What is the most advanced brain technology I can buy?”

It is:

“What threatens my ability to think and function well over the coming decades, and what is the lowest-cost evidence-based action that can materially reduce that risk?”

Brain health is not one number

It is tempting to imagine cognitive ageing as a single curve: memory gradually declines, eventually producing dementia.

Biology is more complicated.

Different capacities can change differently with age. Processing speed may slow while vocabulary remains strong. Hearing loss can make conversation cognitively exhausting without indicating Alzheimer’s disease. Depression, poor sleep, medication effects, thyroid problems, vitamin deficiencies, untreated sleep apnea or vascular disease can impair concentration and memory. Stroke and traumatic brain injury can produce very different cognitive problems from neurodegenerative disease.

Even measurable Alzheimer’s pathology does not map perfectly onto everyday functioning.

A useful brain-health programme therefore needs to protect several assets simultaneously:

Brain-health asset	What we are trying to preserve	High-value interventions
Cognition	Memory, attention, reasoning, processing speed	Learning, physical activity, sleep, vascular-risk control
Executive function	Planning, judgement, adapting to change	Exercise, cognitively demanding activities, health-risk control
Sensory input	Hearing and vision	Hearing/vision checks, appropriate correction, noise protection
Emotional health	Mood, resilience, motivation	Mental-health care, social connection, sleep, exercise
Motor function	Balance, coordination, mobility	Strength, aerobic fitness, balance and mobility training
Cognitive reserve	Capacity to tolerate ageing/pathology while remaining functional	Education, continued learning, complex activities, social engagement
Independence	Ability to manage money, medicines, transport and daily life	All of the above

That last line is ultimately the most important one.

A perfect “brain score” is not the objective.

Functional independence is.

The Guidefinances brain-health hierarchy

The 2024 Lancet Commission identified 14 potentially modifiable dementia risk factors across the life course and estimated that addressing them could theoretically prevent or delay around 45% of dementia cases at population level. The model includes education, hearing loss, high LDL cholesterol, hypertension, smoking, obesity, depression, physical inactivity, diabetes, excessive alcohol, traumatic brain injury, air pollution, social isolation and untreated vision loss.

This does not mean that an individual can reduce his or her dementia probability by exactly 45%. Population-attributable estimates depend on assumptions about causality, prevalence and overlap between risk factors.

But the model makes one important point very clearly:

much of practical brain-health prevention looks remarkably similar to cardiovascular prevention.

The WHO’s updated July 2026 dementia-risk guideline reinforces this approach, emphasizing physical activity, healthy diet, tobacco cessation, lower alcohol exposure, cognitive and social engagement, management of hypertension, diabetes and high cholesterol, hearing care and lower exposure to air pollution.

A reasonable Guidefinances hierarchy is therefore:

A — Foundation

blood-pressure and vascular-risk control
physical activity and cardiorespiratory fitness
strength and metabolic health
adequate sleep
healthy diet
hearing and vision
avoiding tobacco and excessive alcohol
preventing head injury
continued learning
social connection
treatment of depression and other mental-health conditions

B — Targeted

hearing aids when hearing loss is present
sleep-apnea investigation when indicated
neurological or neuropsychological assessment for symptoms
evaluation of reversible causes of cognitive difficulty
targeted blood tests
clinically appropriate brain imaging
genetic counselling/testing in selected circumstances
Alzheimer’s biomarkers when symptoms and clinical context justify them

C — Exploratory / premium

routine “brain-age” MRI in healthy asymptomatic people
repeated proprietary cognitive scores without a clinical action
broad biomarker packages
consumer EEG systems
neurofeedback purchased primarily for longevity
neurostimulation used for enhancement rather than an established medical indication
expensive nootropic stacks
experimental plasmalogen, ketone or “neuro-longevity” products

Spend in roughly that order.

1. Protect the blood vessels that supply the brain

One of the most persistent errors in longevity marketing is treating cardiovascular health and brain health as separate subjects.

They overlap substantially.

The American Heart Association has long argued that many of the behaviours and clinical factors associated with cardiovascular health — smoking, physical activity, diet, body weight, blood pressure, cholesterol and glucose — also provide a practical framework for brain health.

The 2024 Lancet Commission similarly identifies midlife hypertension, high LDL cholesterol, obesity and diabetes among the potentially modifiable factors associated with dementia risk.

This has an important financial implication.

Before purchasing a sophisticated cognitive test, a healthy middle-aged adult can often obtain more actionable information from:

a properly measured blood pressure;
an ordinary lipid profile;
glucose/HbA1c where appropriate;
weight and waist trends;
smoking status;
exercise habits; and
family and medical history.

Our view

A validated €20–100 upper-arm blood-pressure monitor can plausibly provide more actionable long-term brain-health information than an unvalidated €500 “brain optimisation” device.

The cheap measurement wins because there is a well-developed action pathway behind the result.

2. Exercise: probably the most valuable brain-health technology we already have

Exercise is sometimes marketed as a way to increase BDNF, neurogenesis or hippocampal volume.

Those mechanisms are interesting, but they are not the main reason to exercise.

Physical activity simultaneously affects several relevant systems: cardiovascular fitness, blood pressure, glucose regulation, body composition, mobility, mood and sleep. It therefore attacks brain-health risk from several directions at once.

Peter Attia has made exercise particularly central to his brain-health framework:

“There doesn’t appear to be an intervention that is more protective of the brain than exercise.”

Randomized evidence deserves more nuance. A 2024 systematic review of long-duration exercise and multidomain interventions in older adults found that exercise alone did not significantly reduce incident dementia in the available trials, whereas multidomain programmes produced modest cognitive benefits. The evidence for preventing actual dementia remained limited.

That distinction matters.

Exercise has excellent overall health evidence and should be foundational even though we cannot promise that a particular exercise protocol will prevent dementia.

For practical programming, combine:

everyday movement;
aerobic endurance;
cardiorespiratory fitness;
strength;
power;
balance; and
activities that require some coordination and skill.

Exercise involving movement plus cognitive demand — dancing, racket sports, martial arts, complex hiking terrain or learning a new physical skill — may be particularly attractive because it trains more than one system at once.

But a person who prefers cycling and strength training does not need to take up ballroom dancing because a longevity podcast said so.

Adherence remains the dominant variable.

3. Sleep: protect it, but do not oversell the Alzheimer’s story

Sleep clearly matters for attention, learning, memory consolidation, emotional regulation and daytime performance.

The relationship between sleep and dementia is more difficult.

A 2024 systematic review and meta-analysis found substantial associations between very long sleep and future dementia, while the association between short sleep and dementia weakened in studies with follow-up longer than ten years. The authors specifically raised reverse causation: altered sleep may sometimes be an early manifestation of developing disease rather than its cause.

Priorities include:

sufficient sleep opportunity;
regular sleep timing;
treatment of persistent insomnia;
investigation of possible sleep apnea when symptoms warrant it;
appropriate light, noise and temperature conditions.

A premium wearable can sometimes improve adherence.

It should not become a substitute for sleep itself.

4. Hearing may be one of the most underpriced brain-health interventions

Hearing belongs much higher in longevity discussions.

Age-related hearing loss does not merely make sounds quieter. It can increase the cognitive effort required to follow conversation, interfere with communication and reduce social participation.

Hearing loss is one of the modifiable factors in the Lancet dementia model, and WHO’s 2026 dementia-risk guideline says hearing aids may be offered as part of risk-reduction strategies.

The randomized ACHIEVE study adds an important nuance.

Across all 977 participants, the hearing intervention did not significantly slow three-year cognitive decline. However, in the prespecified subgroup recruited from the ARIC cardiovascular cohort — who were older and at higher risk of cognitive decline — the intervention was associated with substantially slower cognitive decline. Later analyses similarly found the largest benefit among participants at highest baseline risk.

Do not buy hearing aids solely because someone promises they prevent dementia.

Do take hearing loss seriously because:

hearing matters directly to quality of life;
effective hearing supports communication;
communication supports social participation;
hearing loss is associated with cognitive decline;
treatment may be particularly valuable in people already carrying other risk factors.

And protect hearing earlier in life. Earplugs at concerts are substantially cheaper than hearing rehabilitation decades later.

5. Vision also belongs in brain health

Untreated vision loss was added as a risk factor in the 2024 Lancet Commission.

The likely relationships are multidimensional. Poor vision can reduce mobility, physical activity, reading, independence and social participation and can increase fall risk.

This again illustrates why “brain health” should not be confined to the skull.

The brain functions through the body and the sensory systems that connect it to the outside world.

Regular vision care and treatment of clinically meaningful visual impairment therefore belong in the foundation/targeted tiers well before elective “brain optimisation” technology.

6. Keep learning — but do not assume every brain game builds cognitive reserve

WHO’s 2026 guidance now specifically includes cognitive training and cognitive stimulation among dementia-risk-reduction interventions. The National Institute on Aging likewise encourages mentally engaging activity.

But the important word is engaging, not “app”.

NIA notes that controlled cognitive-training programmes such as the ACTIVE trial have produced benefits in selected cognitive abilities, while warning that there is insufficient evidence to assume commercially available brain-training games reproduce those results.

A 2025 meta-review similarly found evidence supporting cognitive training, while noting substantial variation in review quality and the need for longer follow-up and better trials.

The cheaper—and arguably richer—approach is to continue doing genuinely difficult things.

Examples include:

learning another language;
learning an instrument;
photography;
writing;
chess or other complex games;
programming;
studying history, mathematics or another unfamiliar subject;
learning new professional skills;
dancing;
navigation;
learning a technically demanding sport;
teaching others.

The relevant characteristic is probably not that one activity is magical.

It is that the brain is repeatedly required to pay attention, make errors, update its model and learn.

Andrew Huberman places particular emphasis on focused attention, active learning, exercise and sleep as interacting components of plasticity. His recent discussions with neuroscientists continue that theme.

That is a useful framework.

It should not be converted into the claim that one precise “neuroplasticity protocol” has been shown to prevent dementia.

7. Social connection is a health intervention — even if its mechanism is messy

WHO includes the ability to build and maintain relationships as a central component of healthy ageing. NIA similarly recommends remaining socially engaged.

The Lancet Commission identifies social isolation as one potentially modifiable dementia-risk factor.

Observational studies generally associate richer social networks and participation with better cognitive outcomes, although causality is difficult because cognitive decline itself may lead people to withdraw socially.

Intervention evidence is less dramatic. A 2024 meta-analysis of social-interaction interventions found benefits for executive function but not clear improvements across all cognitive domains.

This should not discourage social engagement.

The mistake would be requiring dementia prevention to justify friendship.

Social connection also influences:

mental health;
motivation;
physical activity;
sense of purpose;
stress;
adherence to medical care;
independence;
quality of life.

A weekly walk with a friend simultaneously provides social contact, physical activity and environmental stimulation.

That is excellent intervention economics.

8. Mental health is brain health

Depression appears among the potentially modifiable factors associated with dementia in the Lancet framework, although the relationship can run in both directions: depression may contribute to risk, and emerging neurological illness can itself produce depressive symptoms.

NIA similarly advises addressing depression and other physical and mental-health conditions that can affect cognition.

The practical message should therefore remain conservative:

treat depression because depression matters now.

Do not promise that psychotherapy or antidepressant treatment will prevent dementia decades later.

The same applies to anxiety, chronic stress and loneliness.

Brain health should include whether someone is able to concentrate, enjoy life, maintain relationships and act with sufficient motivation—not merely whether an MRI looks youthful.

9. Purpose, meditation and spirituality: valuable categories, different evidence

Longevity discussions sometimes blur three very different questions:

Does an activity improve subjective wellbeing?
Does it measurably affect attention or stress?
Does it prevent neurodegenerative disease?

These are not interchangeable.

Meditation itself has a growing clinical literature. A 2025 meta-analysis of 25 randomized trials in people with subjective cognitive decline, mild cognitive impairment or Alzheimer’s disease reported improvements in some cognitive and sleep outcomes, but heterogeneity, small studies and methodological limitations mean the results should remain provisional.

Meanwhile, observational research associates a stronger sense of purpose with a longer cognitive healthspan, but this too should not be converted into a causal prescription.

Religious and spiritual practices can add something that conventional biomarker research cannot easily capture:

meaning;
community;
ritual;
ethical structure;
acceptance;
perspective on mortality.

Those benefits can be legitimate without pretending that a spiritual practice has been clinically demonstrated to prevent Alzheimer’s disease.

We should keep philosophy, religion and medical evidence in separate columns rather than forcing one to validate the other.

10. Nutrition: think vascular health before “brain food”

There is no need to invent a separate mystical diet for the brain.

A dietary pattern that supports vascular and metabolic health is already doing much of the relevant work: vegetables, fruit, legumes, nuts, appropriate protein, fibre-rich foods, predominantly unsaturated fats and limited reliance on highly processed food.

Specific patterns such as Mediterranean and MIND diets are interesting and observational evidence is generally encouraging, but the useful principles overlap substantially with ordinary cardiovascular nutrition.

This leads to a particularly important 2026 update.

WHO’s new dementia-risk guideline states that, in people without a diagnosed deficiency, it does not recommend vitamins B or E, omega-3 supplements or multivitamin/mineral supplements specifically to reduce cognitive decline or dementia risk because evidence of benefit is insufficient relative to potential harms.

That does not mean that omega-3 fatty acids or vitamins are biologically irrelevant.

It means:

biological relevance is not the same thing as evidence that routine supplementation prevents dementia.

Correct deficiencies.

Eat well.

Do not turn brain health into an automatically recurring supplement bill.

11. Diamandis and the premium brain-optimisation model

Peter Diamandis’ public longevity protocol illustrates the opposite end of the spending spectrum.

His published brain-health section includes omega-3, phosphatidylcholine, plasmalogen products and ketone esters alongside a much broader longevity programme.

This is useful as a catalogue of hypotheses and technologies being explored by a high-resource longevity enthusiast.

It is not a clinical standard.

In particular, claims about plasmalogens, ketone esters or other specialised brain supplements should be separated into three questions:

Is there a plausible mechanism?
Does the intervention improve a measurable human cognitive outcome?
Does it reduce dementia, disability or another clinically meaningful outcome?

Marketing frequently jumps from question one directly to question three.

We should not.

12. What should you actually measure?

Brain-health measurement should escalate only when the result can change a decision.

Tier 1 — Measure the risks around the brain

For most adults this is the highest-value layer:

blood pressure;
lipid profile where appropriate;
glucose/HbA1c when indicated;
hearing;
vision;
smoking/alcohol exposure;
sleep;
physical activity and fitness;
medication review;
mental-health symptoms.

These measurements connect directly to actions.

Tier 2 — Notice functional change

Useful questions include:

Is memory noticeably worsening?
Is work that was previously easy becoming unusually difficult?
Are appointments or medicines repeatedly forgotten?
Are financial tasks becoming confusing?
Is language noticeably changing?
Is navigation becoming difficult?
Are family members noticing a change?
Is there a decline in judgement or everyday independence?

A persistent functional change deserves medical assessment rather than another consumer brain app.

Tier 3 — Formal cognitive assessment

Cognitive screening and neuropsychological testing can be valuable when symptoms, functional changes or clinical circumstances justify them.

But universal testing of healthy asymptomatic people remains unsettled.

The current USPSTF recommendation for asymptomatic community-dwelling adults aged 65 and over concludes that evidence is insufficient to determine the balance of benefits and harms of routine cognitive screening; that recommendation is currently being updated.

This is an important distinction:

a cognitive test can be clinically useful without being something every healthy person needs annually.

Repeated testing also introduces practice effects: sometimes the score improves because the test has become familiar rather than because the brain became younger.

13. Alzheimer’s blood biomarkers: a major advance, but not yet a wellness test

Blood biomarkers are changing dementia medicine rapidly.

In May 2025, the US FDA cleared the first blood test designed to aid diagnosis of Alzheimer’s disease by estimating amyloid pathology using plasma pTau217 and amyloid measurements.

But the indication matters.

The FDA clearance applies to adults aged 55 or older who have signs or symptoms of cognitive decline in a specialised-care context. The FDA explicitly states that the test is not intended as a general screening test or a stand-alone diagnosis.

That qualification should survive the transition from medical technology to longevity marketing.

For an individual with unexplained cognitive decline, a blood biomarker may eventually reduce the need for more invasive or expensive testing.

For a healthy asymptomatic 45-year-old, the value proposition is entirely different.

A positive result can create:

anxiety;
confirmatory testing;
specialist consultations;
imaging;
genetic questions;
insurance and privacy considerations;
treatment decisions with material risks and costs.

The price of the first test is not the real price. The downstream pathway is.

14. APOE and genetic testing: information is useful only if you know what to do with it

APOE genotype influences Alzheimer’s risk, and Attia has discussed knowing APOE status as one component of a personalised brain-health strategy.

Yet genetics illustrates another principle:

risk information has value only if it improves a decision.

Knowing a genetic result can motivate attention to modifiable risk factors.

It can also create psychological burden without changing the fundamental recommendations:

exercise;
control blood pressure;
avoid smoking;
maintain metabolic health;
protect hearing;
remain socially and cognitively active.

Importantly, the Lancet Commission emphasizes that modifiable risk reduction remains relevant irrespective of APOE genetic risk.

Genetic testing is therefore better placed in the targeted rather than foundational tier, ideally with appropriate counselling and a clear understanding of privacy and family implications.

15. “Brain age”: fascinating science, immature consumer metric

AI can now analyse structural MRI and estimate the age a brain most resembles.

The difference between predicted brain age and chronological age — often called a brain-age gap — is being investigated as a biomarker of neurological and psychiatric health.

The research is genuinely interesting.

The consumer interpretation is much less settled.

A 2024 systematic review found that brain-age measures can distinguish groups with several neuropsychiatric conditions, but highlighted major limitations including differences between imaging methods, limited diversity in training data, insufficient external validation and little longitudinal evidence. The authors concluded that these limitations currently impede brain age’s validity as a biological-age marker.

A 2025 review focused specifically on Alzheimer’s disease similarly described brain-age gap as promising while emphasizing site effects, bias correction, interpretability, model accuracy and uncertain clinical applicability.

That places a consumer brain-age result firmly in the Guidefinances exploratory category.

If a €1,000+ scan tells you that your brain is “five years older”, ask:

What validated medical decision changes?

If the answer is merely:

“exercise, sleep, control blood pressure and eat well”,

you could have obtained the prescription for free.

16. MRI: powerful diagnostic tool, weak universal screening argument

Brain MRI is an extraordinarily useful clinical technology.

That does not mean every healthy person benefits from routine repeated MRI.

Imaging can identify tumours, strokes, structural abnormalities and many causes of neurological symptoms when ordered for the right reason.

Screening asymptomatic people introduces a different trade-off:

incidental findings;
uncertain abnormalities;
repeat imaging;
specialist consultations;
anxiety;
additional procedures;
cost.

A premium programme that includes brain MRI may therefore offer genuine convenience and information while still being poor value for a low-risk asymptomatic person.

The correct question is not whether MRI is powerful.

It plainly is.

The question is whether screening this individual at this time is likely to improve an outcome.

17. Nootropics and “brain supplements”: cheap molecule, expensive claim

Brain-health marketing often reverses the evidence hierarchy.

An ingredient may:

cross the blood-brain barrier;
influence a neurotransmitter;
improve a laboratory marker;
produce a small short-term cognitive effect;

and then suddenly be sold as a longevity intervention.

That final step requires much stronger evidence.

WHO’s 2026 recommendation against routine B/E vitamins, omega-3 and multivitamin/mineral supplementation specifically for dementia-risk reduction in people without deficiency is a useful benchmark.

The Guidefinances hierarchy should therefore remain:

food → documented deficiency → targeted supplement → experimental compound.

Not:

podcast → mechanism → shopping basket.

18. What the four reference voices are actually useful for

Reference	Useful contribution	Where Guidefinances agrees	Where evidence discipline begins
Peter Attia	Dementia-risk framework integrating exercise, metabolic health, lipids, sleep, hearing and biomarkers	Brain health should be treated early and systematically	High-resource personalised testing should not automatically become population screening
Andrew Huberman	Neuroplasticity, learning, sleep, exercise, hearing, attention and behavioural tools	Learning and brain health are active processes, not merely disease avoidance	Mechanistic neuroscience should not be converted automatically into preventive clinical recommendations
Peter Diamandis	Technology-forward view of brain health, advanced diagnostics and emerging compounds	New technology deserves observation and testing	Personal supplement protocols and emerging products are hypotheses, not standards of care
Tim Ferriss	Self-experimentation, meditation, learning, mental-health exploration and willingness to test unconventional approaches	Simple repeatable interventions and careful self-observation can be valuable	n=1 experience, meditation philosophy and frontier neurotechnology should remain separate from dementia-prevention evidence

Public experts are most useful as idea generators.

They become less useful when a personal protocol is copied wholesale.

19. The Guidefinances value-for-money ladder

Brain health creates an unusually large spending spectrum.

Level	Intervention	Typical financial burden	Evidence/value
Foundation	Exercise, learning, social engagement, adequate sleep	€0	Exceptional
Foundation	Stop smoking, moderate alcohol, head protection	Often cost-saving	Exceptional
Foundation	Healthy ordinary diet	Often cost-neutral	High
Foundation	Blood-pressure monitoring	Low one-time cost	High
Foundation	Hearing protection	Very low	High
Targeted	Hearing/vision assessment and correction	Varies by health system	High when a problem exists
Targeted	Sleep evaluation, mental-health care, medication review	Varies	High when indicated
Targeted	Neuropsychological assessment	Moderate	Useful for a real cognitive question
Targeted	MRI / specialist neurological investigation	Moderate–high	High when clinically indicated
Targeted/emerging	Alzheimer’s blood biomarkers	Evolving rapidly	Potentially valuable in appropriate symptomatic patients
Exploratory	APOE testing in asymptomatic adults	Low–moderate	Decision-dependent
Exploratory	Consumer brain-age MRI	High	Interesting, limited clinical actionability
Exploratory	Nootropic stacks / proprietary brain supplements	Recurring	Usually poor first expenditure
Exploratory	Enhancement-oriented neurostimulation	High	Specialist/frontier territory

Prices for clinical services vary substantially between Switzerland, the EU and other jurisdictions, and clinically indicated care may be covered partly or fully by insurance.

The ranking matters more than the exact number.

20. A practical brain-health programme

For an otherwise healthy adult, the Guidefinances default could be remarkably simple.

Every day

Move.

Learn something.

Use the brain socially rather than only through screens.

Eat a generally high-quality diet.

Protect sleep.

Do not smoke.

Protect hearing from excessive noise.

Every week

Accumulate meaningful aerobic activity.

Train strength.

Include some difficult cognitive work.

Spend time with other people.

Do something that is genuinely enjoyable rather than treating longevity as another job.

Periodically

Check blood pressure.

Review cardiovascular and metabolic risk.

Check hearing and vision when appropriate.

Review medication if concentration, sleep or memory changes.

Take persistent depression, anxiety or sleep problems seriously.

When something changes

If memory, language, judgement, navigation, behaviour or ability to perform familiar tasks changes persistently, move from “longevity optimisation” to clinical evaluation.

Do not try to solve progressive cognitive symptoms with:

a supplement stack;
a meditation app;
a new wearable;
a brain-training subscription;
a privately generated brain-age score.

Symptoms change the decision tree.

21. What Guidefinances would fund first

Imagine a hypothetical €2,000 annual brain-health budget.

We would not begin by spending €2,000.

We would first ask whether ordinary healthcare already covers the clinically useful components.

The priority would be:

vascular and metabolic prevention;
exercise;
sleep;
hearing and vision;
mental health and social connection;
continued learning;
clinically justified testing.

Only money left after those categories should compete for:

premium MRI;
brain-age algorithms;
extensive biomarker panels;
cognitive subscriptions;
experimental supplements;
enhancement neurotechnology.

And leaving part of the €2,000 unspent can be a perfectly rational result.

Longevity optimisation does not require exhausting the longevity budget.

Continue on Guidefinances

Brain health overlaps with several existing Guidefinances pillars.

Longevity Value

Start with the overall evidence, risk and cost hierarchy. The existing framework places sleep, movement, blood pressure, hearing, nutrition, social connection and appropriate screening ahead of high-uncertainty longevity interventions.

Read Longevity Value

Check-ups

The staged check-up framework is particularly relevant to brain health: history, blood pressure, medication review, hearing, vision, sleep and standard metabolic markers before advanced neuroimaging or biomarker packages.

Read Check-ups: Buy Information in the Right Order

Monitoring

Useful for deciding when wearables, sensors and subscriptions genuinely change behaviour—and when another stream of imperfect data becomes expensive noise.

Read Monitoring: Price the Feed, Not Just the Device

Supplements

Includes omega-3, creatine, vitamins and the more speculative “brain supplement” category, using a food/deficiency-first hierarchy rather than treating supplements as universal dementia prevention.

Read Supplements: From Foundations to Frontier Compounds

Off-the-Shelf Longevity Tools

Includes low-cost blood-pressure, exercise, sleep and habit tools while explicitly warning against unvalidated brain-age gadgets with no action pathway.

Read Off-the-Shelf Tools

Mind, behaviour and self-reflection

The older Guidefinances questionnaire on our relationship with money also touches on psychological wellbeing, curiosity, relationships and maintaining a healthy mind—useful themes for the future mental-health branch of this hub.

Read What Is Your Relationship With Money?

Guidefinances conclusion

Brain health should not become another premium longevity product category.

It should become a framework for protecting capacity.

The capacity to remember.

To learn.

To make decisions.

To hear a conversation.

To navigate.

To control emotions.

To maintain relationships.

To manage money.

To remain physically independent.

To contribute.

That perspective is much closer to the World Health Organization’s concept of healthy ageing than reducing the brain to an MRI number.

It also changes the economics.

The first layer is remarkably inexpensive:

exercise → blood pressure → sleep → nutrition → hearing → vision → learning → relationships → mental health.

The second layer is targeted:

treat the actual problem → investigate symptoms → measure only when the result changes a decision.

And the third layer is where the longevity industry becomes most expensive:

genetics → biomarkers → advanced imaging → brain age → nootropics → neurotechnology.

Some of those technologies will become clinically important.

Some already are—in the correct patient.

But technological sophistication is not the same thing as preventive value.

A youthful brain scan is interesting. The better investment is preserving the ability to live, think, learn and function well without needing the scan to tell you that you can.

Selected evidence and reference sources

World Health Organization — Risk reduction of cognitive decline and dementia, second edition / July 2026 update. Updated recommendations include physical activity, healthy diet, tobacco and alcohol reduction, social and cognitive engagement, cardiometabolic risk management, hearing care and air-pollution reduction.

World Health Organization — Healthy ageing and functional ability. Defines healthy ageing around the ability to meet needs, learn, make decisions, move, maintain relationships and contribute.

US National Institute on Aging — Cognitive Health and Older Adults. Broad overview incorporating physical, cognitive, emotional, sensory and social dimensions of brain health.

Livingston G et al. — Lancet Commission on dementia prevention, intervention and care, 2024. Fourteen potentially modifiable risk factors and a life-course prevention framework.

Lin FR et al. — ACHIEVE randomized trial. Hearing intervention did not significantly alter cognitive decline across the full population but produced encouraging findings in participants at greater baseline risk.

American Heart Association / American Stroke Association — Defining Optimal Brain Health in Adults. Highlights the overlap between cardiovascular and brain-health risk factors.

FDA — First blood test used in diagnosing Alzheimer’s disease. Cleared in 2025 for appropriate symptomatic patients aged 55+; explicitly not a general screening or stand-alone diagnostic test.

USPSTF — Cognitive Impairment in Older Adults: Screening. Current recommendation finds insufficient evidence for routine screening of asymptomatic community-dwelling adults aged 65+, with an update in progress.

Liu S et al. — Brain-age gap as an early Alzheimer’s biomarker, systematic review, 2025. Promising research with substantial model, validation and clinical-translation challenges.

Peter Attia — Brain-health AMAs, 2023–2026. Useful framework around exercise, metabolic health, sleep, hearing, lipids, APOE and evolving biomarkers.

Andrew Huberman — Brain Health, Neuroplasticity and Learning. Useful explanatory material around exercise, learning, sleep, attention and sensory health.

Peter Diamandis — Longevity Practices. Technology-forward personal protocol including several brain-health supplements and experimental strategies that should be distinguished from guideline-level evidence.

Tim Ferriss — brain health, meditation and self-experimentation. Best treated as a source of experimental frameworks rather than universal preventive protocols.

Editorial note: evidence and public reference material reviewed 4 September 2026. Brain-health diagnostics are evolving rapidly, particularly Alzheimer’s blood biomarkers, so availability, indications and regulatory status should be rechecked before purchase or publication updates.

Medical note: this page provides general education and a framework for evaluating health spending. It is not a diagnosis or individual medical recommendation. New or progressive memory, language, behavioural or neurological symptoms require appropriate medical evaluation; sudden neurological changes require urgent assessment.